Kenneth F Baker1, John D Isaacs. 1. The National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, UK.
Abstract
PURPOSE OF REVIEW: To provide an overview of recent advances and future possibilities for therapeutic tolerance. RECENT FINDINGS: Allograft survival despite complete immunosuppressant withdrawal has been demonstrated in selected renal-transplant recipients with haematopoietic chimerism. Early clinical trials of mesenchymal stromal cell therapy have shown promising results in several autoimmune diseases. Regulatory T cells show potential benefit in graft versus host disease, although challenges to ex-vivo expansion remain. Targeted modulation of T-cell function in vivo with monoclonal antibodies has shown beneficial effects in phase II/III trials of multiple sclerosis (alemtuzumab) and type I diabetes mellitus (teplizumab, otelixizumab). Emerging data from animal models suggest an important role for the commensal microbiome in the maintenance and disruption of immune tolerance with parallels in human studies. SUMMARY: After years of slow progress, recent research has reduced the translational gap between animal models and clinical therapeutic tolerance. Early detection of autoimmunity, potentially at preclinical stages, offers a window of opportunity for tolerogenic therapy. Reliable biomarkers of tolerance are urgently needed to provide objective measurements of the effectiveness of tolerogenic therapies, and to allow intelligent immunosuppressant withdrawal in patients whose autoimmune disease is stable. VIDEO ABSTRACT AVAILABLE: See the Video Supplementary Digital Content 1 (http://links.lww.com/COR/A8).
PURPOSE OF REVIEW: To provide an overview of recent advances and future possibilities for therapeutic tolerance. RECENT FINDINGS: Allograft survival despite complete immunosuppressant withdrawal has been demonstrated in selected renal-transplant recipients with haematopoietic chimerism. Early clinical trials of mesenchymal stromal cell therapy have shown promising results in several autoimmune diseases. Regulatory T cells show potential benefit in graft versus host disease, although challenges to ex-vivo expansion remain. Targeted modulation of T-cell function in vivo with monoclonal antibodies has shown beneficial effects in phase II/III trials of multiple sclerosis (alemtuzumab) and type I diabetes mellitus (teplizumab, otelixizumab). Emerging data from animal models suggest an important role for the commensal microbiome in the maintenance and disruption of immune tolerance with parallels in human studies. SUMMARY: After years of slow progress, recent research has reduced the translational gap between animal models and clinical therapeutic tolerance. Early detection of autoimmunity, potentially at preclinical stages, offers a window of opportunity for tolerogenic therapy. Reliable biomarkers of tolerance are urgently needed to provide objective measurements of the effectiveness of tolerogenic therapies, and to allow intelligent immunosuppressant withdrawal in patients whose autoimmune disease is stable. VIDEO ABSTRACT AVAILABLE: See the Video Supplementary Digital Content 1 (http://links.lww.com/COR/A8).
Authors: L von Bahr; I Batsis; G Moll; M Hägg; A Szakos; B Sundberg; M Uzunel; O Ringden; K Le Blanc Journal: Stem Cells Date: 2012-07 Impact factor: 6.277
Authors: Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner Journal: Blood Date: 2010-10-15 Impact factor: 22.113
Authors: Sheila L Arvikar; Deborah S Collier; Mark C Fisher; Sebastian Unizony; George L Cohen; Gail McHugh; Toshihisa Kawai; Klemen Strle; Allen C Steere Journal: Arthritis Res Ther Date: 2013 Impact factor: 5.156
Authors: C Graham; R Chooniedass; W P Stefura; L Lotoski; P Lopez; A D Befus; A B Becker; K T HayGlass Journal: J Transl Med Date: 2017-03-02 Impact factor: 5.531
Authors: Christian Kleist; Elisabeth Mohr; Sadanand Gaikwad; Laura Dittmar; Stefanie Kuerten; Michael Platten; Walter Mier; Michael Schmitt; Gerhard Opelz; Peter Terness Journal: J Transl Med Date: 2016-05-01 Impact factor: 5.531